AU2007244005B2 - Further medical uses of antisecretory protein - Google Patents

Further medical uses of antisecretory protein Download PDF

Info

Publication number
AU2007244005B2
AU2007244005B2 AU2007244005A AU2007244005A AU2007244005B2 AU 2007244005 B2 AU2007244005 B2 AU 2007244005B2 AU 2007244005 A AU2007244005 A AU 2007244005A AU 2007244005 A AU2007244005 A AU 2007244005A AU 2007244005 B2 AU2007244005 B2 AU 2007244005B2
Authority
AU
Australia
Prior art keywords
dysfunction
use according
treatment
antisecretory
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007244005A
Other languages
English (en)
Other versions
AU2007244005A1 (en
Inventor
Hans-Arne Hansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LANTMANNEN AS-FAKTOR AB
Original Assignee
Lantmannen AS Faktor AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmannen AS Faktor AB filed Critical Lantmannen AS Faktor AB
Publication of AU2007244005A1 publication Critical patent/AU2007244005A1/en
Assigned to LANTMANNEN AS-FAKTOR AB reassignment LANTMANNEN AS-FAKTOR AB Alteration of Name(s) of Applicant(s) under S113 Assignors: LANTMANNEN AS-FAKTOR
Application granted granted Critical
Publication of AU2007244005B2 publication Critical patent/AU2007244005B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2007244005A 2006-04-27 2007-04-27 Further medical uses of antisecretory protein Ceased AU2007244005B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0600933-6 2006-04-27
SE0600933 2006-04-27
US92082607P 2007-03-30 2007-03-30
US60/920,826 2007-03-30
PCT/SE2007/000415 WO2007126365A2 (en) 2006-04-27 2007-04-27 Further medical uses of antisecretory protein

Publications (2)

Publication Number Publication Date
AU2007244005A1 AU2007244005A1 (en) 2007-11-08
AU2007244005B2 true AU2007244005B2 (en) 2012-08-02

Family

ID=38655930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007244005A Ceased AU2007244005B2 (en) 2006-04-27 2007-04-27 Further medical uses of antisecretory protein

Country Status (10)

Country Link
US (1) US8487074B2 (enExample)
EP (1) EP2037950B1 (enExample)
JP (2) JP5508846B2 (enExample)
KR (1) KR20090037992A (enExample)
AU (1) AU2007244005B2 (enExample)
CA (1) CA2650132C (enExample)
IL (1) IL194775A (enExample)
MX (1) MX2008013777A (enExample)
PL (1) PL2037950T3 (enExample)
WO (1) WO2007126365A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US8901083B2 (en) 2008-11-25 2014-12-02 Temple University Administration of angiocidin for the treatment of leukemia
JP5820277B2 (ja) 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2022159845A1 (en) * 2021-01-22 2022-07-28 University Of Virginia Patent Foudation Altering protein function by pharmacological targeting of membrane domains

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030246A1 (en) * 2003-09-26 2005-04-07 As-Faktor Ab Novel use of antisecretory factor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) * 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
EP2682819A2 (en) * 2012-07-04 2014-01-08 Xeikon IP B.V. A method for forming a multi-colour image

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030246A1 (en) * 2003-09-26 2005-04-07 As-Faktor Ab Novel use of antisecretory factor

Also Published As

Publication number Publication date
US20090149382A1 (en) 2009-06-11
MX2008013777A (es) 2009-02-03
KR20090037992A (ko) 2009-04-17
WO2007126365A2 (en) 2007-11-08
EP2037950B1 (en) 2014-04-23
JP5508846B2 (ja) 2014-06-04
AU2007244005A1 (en) 2007-11-08
PL2037950T3 (pl) 2014-09-30
IL194775A0 (en) 2011-08-01
HK1128237A1 (en) 2009-10-23
WO2007126365A8 (en) 2009-03-05
JP2009535330A (ja) 2009-10-01
JP2014111623A (ja) 2014-06-19
EP2037950A2 (en) 2009-03-25
IL194775A (en) 2015-09-24
CA2650132C (en) 2017-10-24
US8487074B2 (en) 2013-07-16
WO2007126365A3 (en) 2008-03-13
JP6063401B2 (ja) 2017-01-18
CA2650132A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
US8487074B2 (en) Modulation of lipid rafts
RU2457853C2 (ru) Модуляция липидных рафтов
DK2015767T3 (en) APPLICATION OF ANTISECRETORIC FACTOR TO TREAT INTRAOCULAR HYPERTENSION
US11229675B2 (en) Therapeutic peptides for excitatory neurotoxicity-related injuries
KR20120084765A (ko) 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
HK1128237B (en) Further medical uses of antisecretory protein
CN112368014B (zh) 抗分泌因子在治疗和/或预防急性呼吸衰竭中的用途
HK1156529B (en) Antisecretory protein for use in the treatment of compartiment syndrome
HK1156529A (en) Antisecretory protein for use in the treatment of compartiment syndrome
HK1131738B (en) Antisecretory protein for use in the treatment of compartment syndrome

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HANSSON, HANS-ARNE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired